Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T15722
(Former ID: TTDI02540)
|
|||||
| Target Name |
Cyclin-dependent kinase 11B (CDK11B)
|
|||||
| Synonyms |
p58 CLK1; p58 CLK-1; PK58; PITSLREA; PITSLRE serine/threonineprotein kinase CDC2L1; PITSLRE serine/threonine-protein kinase CDC2L1; Galactosyltransferaseassociated protein kinase p58/GTA; Galactosyltransferase-associated protein kinase p58/GTA; Cyclindependent kinase 11B; Cell division protein kinase 11B; Cell division cycle 2-like protein kinase 1; CLK-1; CDK11; CDC2L1
Click to Show/Hide
|
|||||
| Gene Name |
CDK11B
|
|||||
| Target Type |
Literature-reported target
|
[1] | ||||
| Function |
Involved in pre-mRNA splicing in a kinase activity-dependent manner. Isoform 7 may act as a negative regulator of normal cell cycle progression. Plays multiple roles in cell cycle progression, cytokinesis and apoptosis.
Click to Show/Hide
|
|||||
| BioChemical Class |
Kinase
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 2.7.11.22
|
|||||
| Sequence |
MGDEKDSWKVKTLDEILQEKKRRKEQEEKAEIKRLKNSDDRDSKRDSLEEGELRDHRMEI
TIRNSPYRREDSMEDRGEEDDSLAIKPPQQMSRKEKAHHRKDEKRKEKRRHRSHSAEGGK HARVKEKEREHERRKRHREEQDKARREWERQKRREMAREHSRRERDRLEQLERKRERERK MREQQKEQREQKERERRAEERRKEREARREVSAHHRTMREDYSDKVKASHWSRSPPRPPR ERFELGDGRKPGEARPAPAQKPAQLKEEKMEERDLLSDLQDISDSERKTSSAESSSAESG SGSEEEEEEEEEEEEEGSTSEESEEEEEEEEEEEEETGSNSEEASEQSAEEVSEEEMSED EERENENHLLVVPESRFDRDSGESEEAEEEVGEGTPQSSALTEGDYVPDSPALSPIELKQ ELPKYLPALQGCRSVEEFQCLNRIEEGTYGVVYRAKDKKTDEIVALKRLKMEKEKEGFPI TSLREINTILKAQHPNIVTVREIVVGSNMDKIYIVMNYVEHDLKSLMETMKQPFLPGEVK TLMIQLLRGVKHLHDNWILHRDLKTSNLLLSHAGILKVGDFGLAREYGSPLKAYTPVVVT LWYRAPELLLGAKEYSTAVDMWSVGCIFGELLTQKPLFPGKSEIDQINKVFKDLGTPSEK IWPGYSELPAVKKMTFSEHPYNNLRKRFGALLSDQGFDLMNKFLTYFPGRRISAEDGLKH EYFRETPLPIDPSMFPTWPAKSEQQRVKRGTSPRPPEGGLGYSQLGDDDLKETGFHLTTT NQGASAAGPGFSLKF Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: OTS964 | Ligand Info | |||||
| Structure Description | CDK11 in complex with small molecule inhibitor OTS964 | PDB:7UKZ | ||||
| Method | X-ray diffraction | Resolution | 2.60 Å | Mutation | No | [2] |
| PDB Sequence |
EEFQCLNRIE
89 EGTYGVVYRA99 KDKEIVALKR112 LKMEKEKEFP123 ITSLREINTI133 LKAQHPNIVT 143 VREIVVGSNM153 DKIYIVMNYV163 EHDLKSLMET173 MKQPFLPGEV183 KTLMIQLLRG 193 VKHLHDNWIL203 HRDLKTSNLL213 LSHAGILKVG223 DFGLAREYGS233 PLKAYPVVVT 244 LWYRAPELLL254 GAKEYSTAVD264 MWSVGCIFGE274 LLTQKPLFPG284 KSEIDQINKV 294 FKDLGTPSEK304 IWPGYSELPA314 VKKMTFSEHP324 YRKRFGALLS337 DQGFDLMNKF 347 LTYFPGRRIS357 AEDGLKHEYF367 RETPLPIDPS377 MFPKL
|
|||||
|
|
ILE88
3.447
GLU89
3.680
GLU90
3.670
GLY91
3.611
GLY94
4.782
VAL96
3.509
ALA109
3.511
LYS111
4.533
VAL142
4.533
MET160
3.397
ASN161
3.839
|
|||||
| Ligand Name: Phosphonothreonine | Ligand Info | |||||
| Structure Description | CDK11 in complex with small molecule inhibitor OTS964 | PDB:7UKZ | ||||
| Method | X-ray diffraction | Resolution | 2.60 Å | Mutation | No | [2] |
| PDB Sequence |
EEFQCLNRIE
89 EGTYGVVYRA99 KDKEIVALKR112 LKMEKEKEFP123 ITSLREINTI133 LKAQHPNIVT 143 VREIVVGSNM153 DKIYIVMNYV163 EHDLKSLMET173 MKQPFLPGEV183 KTLMIQLLRG 193 VKHLHDNWIL203 HRDLKTSNLL213 LSHAGILKVG223 DFGLAREYGS233 PLKAYPVVVT 244 LWYRAPELLL254 GAKEYSTAVD264 MWSVGCIFGE274 LLTQKPLFPG284 KSEIDQINKV 294 FKDLGTPSEK304 IWPGYSELPA314 VKKMTFSEHP324 YRKRFGALLS337 DQGFDLMNKF 347 LTYFPGRRIS357 AEDGLKHEYF367 RETPLPIDPS377 MFPKL
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Biological Network Descriptors
|
|
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
| Degree | 1 | Degree centrality | 1.07E-04 | Betweenness centrality | 0.00E+00 |
|---|---|---|---|---|---|
| Closeness centrality | 1.83E-01 | Radiality | 1.31E+01 | Clustering coefficient | 0.00E+00 |
| Neighborhood connectivity | 2.30E+01 | Topological coefficient | 1.00E+00 | Eccentricity | 13 |
| Download | Click to Download the Full PPI Network of This Target | ||||
| Target Regulators | Top | |||||
|---|---|---|---|---|---|---|
| Target-interacting Proteins | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Identification and characterization of the BmCyclin L1-BmCDK11A/B complex in relation to cell cycle regulation. Cell Cycle. 2017 May 3;16(9):861-868. | |||||
| REF 2 | Crystal structure of the CDK11 kinase domain bound to the small-molecule inhibitor OTS964. Structure. 2022 Dec 1;30(12):1615-1625.e4. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.